Drug intelligence / Profile preview

Org 24598

Development stage
Preclinical
Lead developer
Organon
Modality
Small Molecules
Administration
Unknown
01

Overview

Org 24598 is a potent and highly selective small molecule inhibitor of the glial glycine transporter GlyT1 (specifically GlyT1b, with IC50 = 6.9 nM). It displays negligible activity on GlyT2 and other monoaminergic systems, including adrenoreceptors, dopamine, 5HT receptors, and noradrenaline, dopamine, 5HT and GABA transporters. In preclinical studies, Org 24598 has demonstrated efficacy in modulating glycine neurotransmission and enhancing NMDA receptor function. It has been shown to improve cognitive flexibility and memory deficits following binge-like ethanol exposure and to reduce alcohol intake in animal models, likely through increased glycine receptor neurotransmission. Org 24598 has also inhibited the reacquisition of cocaine self-administration in preclinical addiction models, suggesting potential utility in substance use disorders and cognitive dysfunction. Its chemical structure is N-Methyl-N-[(3R)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-glycine, and it is available as the lithium salt for research use[1][3][5][7][8][9].

Other names
R-(−)-N-Methyl-N-[3-[(4-trifluoromethyl)phenoxy]-3-phenyl-propyl]glycineOrg-24598 lithium saltOrg24598 lithium saltOrg 24598 lithium saltN-Methyl-N-[(3R)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-glycine
02

Targets

GlyT1 (Sodium- and chloride-dependent glycine transporter 1)

Beyond the preview

Go deeper on Org 24598.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Org 24598.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call